Juvena Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Juvena Therapeutics - overview
Established
2017
Location
Redwood City, CA, US
Primary Industry
Biotechnology
About
Based in California, US, Juvena Therapeutics Inc. operates as a biotech firm that develops biologics for aging-related diseases. The company was founded by its CEO Hanadie Yousef, and CSO Jeremy O’Connell. In November 2022, Juvena Therapeutics Inc.
raised USD 41 million in Series A funding, co-led by Horizons Ventures, Alumni Ventures Group, Bison Ventures, and Compound Ventures. Juvena Therapeutics provides an artificial intelligence-based biologics drug development platform that is a machine learning-enabled platform for drug discovery and creates stem cell-secreted proteins and biologics for age- and chronic-related disorders. The company develops drugs through its pipeline project, JUV-161, which is a fusion protein therapeutic programme used for the treatment of neuromuscular diseases. The company plans to use the funds raised in November 2022 to expand its manpower and strengthen its platform.
Current Investors
Compound Ventures, Felicis Ventures, Horizons Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Bioinformatics
Website
www.juvenatherapeutics.com
Verticals
Artificial Intelligence, HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.